PharmacoEconomics

, Volume 18, Issue 4, pp 317–333 | Cite as

Cost Effectiveness of Therapies for Atrial Fibrillation

A Review
  • Mark P. Teng
  • Edward Catherwood
  • Daniel P. Melby
Review Article

Abstract

Atrial fibrillation is the most common supraventricular tachyarrhythmia encountered in clinical practice, affecting over 5% of persons over the age of 65 years. A common pathophysiological mechanism for arrhythmia development is atrial distention and fibrosis induced by hypertension, coronary artery disease or ventricular dysfunction. Less frequently, atrial fibrillation is caused by mitral stenosis or other provocative factors such as thyrotoxicosis, pericarditis or alcohol intoxication. Depending on the extent of associated cardiovascular disease, atrial fibrillation may produce haemodynamic compromise, or symptoms such as palpitations, fatigue, chest pain or dyspnoea. Arrhythmia-induced atrial stasis can precipitate clot formation and the potential for subsequent thromboembolism.

Comprehensive management of atrial fibrillation requires a multifaceted approach directed at controlling symptoms, protecting the patient from ischaemic stroke or peripheral embolismand possible conversion to ormaintenance of sinus rhythm. Numerous randomised trials have demonstrated the efficacy of warfarin — and less so aspirin (acetylsalicylic acid) — in reducing the risk of embolic events. Furthermore, therapeutic strategies exist that can favourably modify symptoms by restoring and maintaining sinus rhythm with cardioversion and antiarrhythmic prophylaxis. However, the risks and benefits of various treatments is highly dependent on patient-specific features, emphasising the need for an individualised approach.

This article reviews the findings of cost-effectiveness studies published over the past decade that have evaluated different components of treatment strategies for atrial fibrillation. These studies demonstrate the economic attractiveness of acute management options, long term warfarin prophylaxis, telemetry-guided initiation of antiarrhythmic therapy, approaches to restore and maintain sinus rhythm, and the potential role of transoesophageal echocardiographic screening for atrial thrombus prior to pharmacological or electrical cardioversion. Further, we discuss the merits and limitations of the cost-effectiveness analyses in the context of overall treatment strategies. Finally, we identify areas that will require additional research to achieve the goal of effective and economically efficient management of atrial fibrillation.

References

  1. 1.
    Prystowsky EN, Benson W, Fuster V, et al. Management of patients with atrial fibrillation. A statement for healthcare professionals from the subcommittee on electrocardiography and electrophysiology. American Heart Association. Circulation 1996; 93: 1262–77PubMedCrossRefGoogle Scholar
  2. 2.
    Blackshear JL, Kopecky SL, Litin SC, et al. Management of atrial fibrillation in adults: prevention of thromboembolism and symptomatic treatment. Mayo Clin Proc 1996; 71 (2): 150–60PubMedCrossRefGoogle Scholar
  3. 3.
    Mackstaller LL, Alpert JS. Atrial fibrillation: a review of mechanism, etiology, and therapy. Clin Cardiol 1997; 20: 640–50PubMedCrossRefGoogle Scholar
  4. 4.
    Feinberg WM, Blackshear JL, LaupacisA, et al. Prevalence, age distribution, and gender of patients with atrial fibrillation. Analysis and implications. Arch Intern Med 1995; 155: 469–73PubMedCrossRefGoogle Scholar
  5. 5.
    Wolf PA, Benjamin EJ, Belanger AJ, et al. Secular trends in the prevalence of atrial fibrillation: the Framingham study. Am Heart J 1996; 131: 790–5PubMedCrossRefGoogle Scholar
  6. 6.
    Kopecky SL, Gersh BJ, McGoon MD, et al. The natural history of lone atrial fibrillation. A population-based study over three decades. N Engl J Med 1987; 317: 669–74PubMedCrossRefGoogle Scholar
  7. 7.
    Janse M, Allessie M. Experimental observations on atrial fibrillation. In: Falk R, Podrid P, editors. Atrial fibrillation. Mechanisms and management. 2nd ed. Philadelphia (PA): Lippincott-Raven; 1997: 53–73Google Scholar
  8. 8.
    Wijffels M, Kirchhof C, Dorland R, et al. Atrial fibrillation begets atrial fibrillation: a study in awake chronically instrumented goats. Circulation 1995; 92: 1954–68PubMedCrossRefGoogle Scholar
  9. 9.
    Aboaf AP, Wolf PS. Paroxysmal atrial fibrillation. A common but neglected entity. Arch Intern Med 1996; 156: 362–7PubMedCrossRefGoogle Scholar
  10. 10.
    Grogan M, Smith H, Gersh B, et al. Left ventricular dysfunction due to atrial fibrillation in patients initially believed to have idiopathic cardiomyopathy. Am J Cardiol 1992; 69: 1570–3PubMedCrossRefGoogle Scholar
  11. 11.
    Gosselink ATM, Crijns HJGM, Van Den Berg MP, et al. Functional capacity before and after cardioversion of atrial fibrillation: a controlled study. Br Heart J 1994; 72: 161–6PubMedCrossRefGoogle Scholar
  12. 12.
    Upshaw CB. Hemodynamic changes after cardioversion of chronic atrial fibrillation. Arch Intern Med 1997; 157: 1070–6PubMedCrossRefGoogle Scholar
  13. 13.
    Wolf PA, Abbott RD, Kannel WB. Atrial fibrillation as an independent risk factor for stroke: The Framingham study. Stroke 1991; 22: 983–8PubMedCrossRefGoogle Scholar
  14. 14.
    Lin H, Wolf P, Benjamin E, et al. Newly diagnosed atrial fibrillation and acute stroke. Stroke 1995; 26: 1527–30PubMedCrossRefGoogle Scholar
  15. 15.
    Albers GW. Atrial fibrillation and stroke. Three new studies, three remaining questions. Arch Intern Med 1994; 154 (13): 1443–8PubMedCrossRefGoogle Scholar
  16. 16.
    Atrial Fibrillation Investigators. Risk factors for stroke and efficacy of antithrombotic therapy in atrial fibrillation. Analysis of pooled data from five randomized controlled trials. Arch Intern Med 1994; 154 (13): 1449–57CrossRefGoogle Scholar
  17. 17.
    Kottkamp H, Hindricks G, Breithardt G. Role of anticoagulant therapy in atrial fibrillation. J Cardiovasc Electrophysiol 1998; 9: S86–96Google Scholar
  18. 18.
    Laupacis A, Albers G, Dalen J, et al. Antithrombotic therapy in atrial fibrillation. Chest 1998; 114: 579S-89SCrossRefGoogle Scholar
  19. 19.
    Hart R, Benavente O,McBride R, et al. Antithrombotic therapy to prevent stroke in patients with atrial fibrillation: a meta-analysis. Ann Intern Med 1999; 131: 492–501PubMedGoogle Scholar
  20. 20.
    Stöllberger C, Chnupa P, Kronik G, et al. Transoesophageal echocardiography to assess embolic risk in patients with atrial fibrillation. Ann Intern Med 1998; 128: 630–8PubMedGoogle Scholar
  21. 21.
    Stroke Prevention in Atrial Fibrillation Investigators Committee on Echocardiography. Transesophageal echocardiographic correlates of thromboembolism in high-risk patients with nonvalvular atrial fibrillation. Ann InternMed 1998; 128: 639–47Google Scholar
  22. 22.
    Stroke Prevention in Atrial Fibrillation Investigators. Predictors of thromboembolism in atrial fibrillation: II. Echocardiographic features of patients at risk. Ann Intern Med 1992; 116 (1): 6–12Google Scholar
  23. 23.
    Stroke Prevention in Atrial Fibrillation Investigators. Patients with nonvalvular atrial fibrillation at low risk of stroke during treatment with aspirin: Stroke Prevention in Atrial Fibrillation III study. JAMA 1998; 279: 1273–7CrossRefGoogle Scholar
  24. 24.
    Hart R, Pearce L, Rothbart R, et al. Stroke with intermittent atrial fibrillation: incidence and predictors during aspirin therapy. J Am Coll Cardiol 2000; 35: 183–7PubMedCrossRefGoogle Scholar
  25. 25.
    Weigner MJ, Caulfield TA, Danias PG, et al. Risk for clinical thromboembolism associated with conversion to sinus rhythm in patients with atrial fibrillation lasting less than 48 hours. Ann Intern Med 1997; 126 (8): 615–20PubMedGoogle Scholar
  26. 26.
    Dell’ Orfano JT, Kramer RK, Naccarelli GV. Cost-effective strategies in the acute management of atrial fibrillation. Curr Opin Cardiol 2000; 15 (1): 23–8CrossRefGoogle Scholar
  27. 27.
    Danias P, Caulfield T, Weigner M, et al. Likelihood of spontaneous conversion of atrial fibrillation to sinus rhythm. J Am Coll Cardiol 1998; 31: 588–92PubMedCrossRefGoogle Scholar
  28. 28.
    Prystowsky EN. Management of atrial fibrillation: simplicity surrounded by controversy. Ann Intern Med 1997; 126: 244–6PubMedGoogle Scholar
  29. 29.
    Grimm R, Stewart W, Black I, et al. Should all patients undergo transesophageal echocardiography before electrical cardioversion of atrial fibrillation. J Am Coll Cardiol 1994; 23: 533–41PubMedCrossRefGoogle Scholar
  30. 30.
    Manning W, Weintraub R, Waksmonski C, et al. Accuracy of transesophageal echocardiography for identifying left atrial thrombi. Ann Intern Med 1995; 123: 817–22PubMedGoogle Scholar
  31. 31.
    Manning W, Silverman D, Keighley C, et al. Transesophageal echocardiographically facilitated early cardioversion from atrial fibrillation using short-term anticoagulation: final results of a prospective 4.5-year study. J Am Coll Cardiol 1995; 25: 1354–61PubMedCrossRefGoogle Scholar
  32. 32.
    Torrance GW, Siegel JE, Luce BR. Framing and designing the cost-effectiveness analysis. In: Gold MR, Siegel JE, Russell LB, et al., editors. Cost-effectiveness in health and medicine. New York (NY): Oxford University Press, 1996: 54–81Google Scholar
  33. 33.
    Pauker SG, Kassirer JP. Decision analysis. N Engl J Med 1987; 316: 250–8PubMedCrossRefGoogle Scholar
  34. 34.
    Detsky AS, Naglie IG. A clinician’s guide to cost-effectiveness analysis. Ann Intern Med 1990; 113: 147–54PubMedGoogle Scholar
  35. 35.
    Kupersmith J, Holmes-Rovner M, Hogan A, et al. Cost-effectiveness analysis in heart disease, Part I: general principles. Prog Cardiovasc Dis 1994 Nov/Dec; 37 (3): 161–84PubMedCrossRefGoogle Scholar
  36. 36.
    Sonnenberg FA, Beck JR. Markov models in medical decision making: a practical guide. Med Decis Making 1993; 13: 322–38PubMedCrossRefGoogle Scholar
  37. 37.
    Torrance GW. Utility approach to measuring health-related quality of life. J Chronic Dis 1987; 40: 593–603PubMedCrossRefGoogle Scholar
  38. 38.
    Gage BF, Cardinalli AB, Owens DK. The effect of stroke and stroke prophylaxis with aspirin or warfarin on quality of life. Arch Intern Med 1996; 156: 1829–36PubMedCrossRefGoogle Scholar
  39. 39.
    Laupacis A, Feeny D, Detsky A, et al. How attractive does a new technology have to be to warrant adoption and utilization? Tentative guidelines and economic evaluations. Can Med Assoc J 1993; 148: 913–7Google Scholar
  40. 40.
    Eckman MH, Falk RH, Pauker SG. Cost-effectiveness of therapies for patients with nonvalvular atrial fibrillation. Arch Intern Med 1998; 158 (15): 1669–77PubMedCrossRefGoogle Scholar
  41. 41.
    Manning WG, Fryback DG, Weinstein MC. Reflecting uncertainty in cost-effectiveness analysis. In: Gold MR, Siegel JE, Russell LB, et al., editors. Cost-effectiveness in health and medicine. New York (NY): Oxford University Press, 1996: 247–75Google Scholar
  42. 42.
    Petersen P, Boysen G, Godtfredsen J, et al. Placebo-controlled, randomised trial of warfarin and aspirin for prevention of thromboembolic complications in chronic atrial fibrillation. The Copenhagen AFASAK study. Lancet 1989; I: 175–9CrossRefGoogle Scholar
  43. 43.
    The Boston Area Anticoagulation Trial for Atrial Fibrillation Investigators. The effect of low-dose warfarin on the risk of stroke in patients with nonrheumatic atrial fibrillation. N Engl J Med 1990; 323 (22): 1505–11Google Scholar
  44. 44.
    Connolly SJ, Laupacis A, GentM, et al. Canadian Atrial Fibrillation Anticoagulation (CAFA) Study. J Am Coll Cardiol 1991; 18 (2): 349–55PubMedCrossRefGoogle Scholar
  45. 45.
    Ezekowitz MD, Bridgers SL, James KE, et al. Warfarin in the prevention of stroke associated with nonrheumatic atrial fibrillation. Veterans Affairs Stroke Prevention in Nonrheumatic Atrial Fibrillation Investigators. N Engl J Med 1992; 327 (20): 1406–12PubMedCrossRefGoogle Scholar
  46. 46.
    Stroke Prevention in Atrial Fibrillation Investigators. Stroke Prevention in Atrial Fibrillation Study. Final results. Circulation 1991; 84 (2): 527–39Google Scholar
  47. 47.
    European Atrial Fibrillation Trial Study Group. Secondary prevention in non-rheumatic atrial fibrillation after transient ischaemic attack or minor stroke. Lancet 1993; 342: 1255–62Google Scholar
  48. 48.
    Gustafsson C, Asplund K, Britton M, et al. Cost effectiveness of primary stroke prevention in atrial fibrillation: Swedish national perspective. BMJ 1992; 305 (6867): 1457–60PubMedCrossRefGoogle Scholar
  49. 49.
    Gage BF, Cardinalli AB, Albers GW, et al. Cost-effectiveness of warfarin and aspirin for prophylaxis of stroke in patients with nonvalvular atrial fibrillation. JAMA 1995; 274 (23): 1839–45PubMedCrossRefGoogle Scholar
  50. 50.
    Lightowlers S, McGuire A. Cost-effectiveness of anticoagulation in nonrheumatic atrial fibrillation in the primary prevention of ischemic stroke. Stroke 1998; 29 (9): 1827–32PubMedCrossRefGoogle Scholar
  51. 51.
    Eckman MH, Levine HJ, Salem DN, et al. Making decisions about antithrombotic therapy in heart disease: decision analytic and cost-effectiveness issues. Chest 1998; 114: 699S-714SCrossRefGoogle Scholar
  52. 52.
    Catherwood E, Fitzpatrick WD, Greenberg ML, et al. Cost-effectiveness of cardioversion and antiarrhythmic therapy in nonvalvular atrial fibrillation. Ann Intern Med 1999; 130 (8): 625–36PubMedGoogle Scholar
  53. 53.
    Hylek EM, Skates SJ, Sheehan MA, et al. An analysis of the lowest effective intensity of prophylactic anticoagulation for patients with nonrheumatic atrial fibrillation. N Engl J Med 1996; 335 (8): 540–6PubMedCrossRefGoogle Scholar
  54. 54.
    European Atrial Fibrillation Trial Study Group. Optimal oral anticoagulation therapy in patients with nonrheumatic atrial fibrillation and recent cerebral ischemia. N Engl JMed 1995; 333: 5–10CrossRefGoogle Scholar
  55. 55.
    Hirsh J, Dalen JE, Deykin D, et al. Oral anticoagulants. Mechanism of action, clinical effectiveness, and optimal therapeutic range. Chest 1995; 108 (4): 231S-46SCrossRefGoogle Scholar
  56. 56.
    Whittle J, Wickenheiser L, Venditti LN. Is warfarin underused in the treatment of elderly persons with atrial fibrillation? Arch Intern Med 1997; 157 (4): 441–5PubMedCrossRefGoogle Scholar
  57. 57.
    Brass LM, Krumholz HM, Scinto JD, et al. Warfarin use following ischemic stroke among Medicare patients with atrial fibrillation. Arch Intern Med 1998; 158 (19): 2093–100PubMedCrossRefGoogle Scholar
  58. 58.
    Chiquette E, Amato MG, Bussey HI. Comparison of an anticoagulation clinic with usual medical care. Arch Intern Med 1998; 158: 1641–7PubMedCrossRefGoogle Scholar
  59. 59.
    Petty GW, Brown RD, Whisnant JP, et al. Frequency of major complications of aspirin, warfarin, and intravenous heparin for secondary stroke prevention. Ann Intern Med 1999; 130: 14–22PubMedGoogle Scholar
  60. 60.
    Levine MN, Raskob G, Landefield S, et al. Hemorrhagic complications of anticoagulant treatment. Chest 1995; 108 (4): 276S-90SCrossRefGoogle Scholar
  61. 61.
    The Stroke Prevention in Atrial Fibrillation Investigators. Bleeding during antithrombotic therapy in patients with atrial fibrillation. Arch Intern Med 1996; 156 (4): 409–16CrossRefGoogle Scholar
  62. 62.
    Ellenbogen KA, Clemo HF, Stambler BS, et al. Efficacy of ibutilide for termination of atrial fibrillation and flutter. Am J Cardiol 1996; 78 (8A): 42–5PubMedCrossRefGoogle Scholar
  63. 63.
    Foster RH, Wilde MI, Markham A. Ibutilide: a review of its pharmacological properties and clinical potential in the acute management of atrial flutter and fibrillation. Drugs 1997; 54 (2): 312–30PubMedCrossRefGoogle Scholar
  64. 64.
    Oral H, Souza JJ, Michaud GF, et al. Facilitating transthoracic cardioversion of atrial fibrillation with ibutilide pretreatment. N Engl J Med 1999; 340 (24): 1849–54PubMedCrossRefGoogle Scholar
  65. 65.
    Di Benedetto S. Quinidine versus propafenone for conversion of atrial fibrillation to sinus rhythm. Am J Cardiol 1997; 80 (4): 518–9PubMedCrossRefGoogle Scholar
  66. 66.
    Grace AA, Camm AJ. Quinidine. N Engl J Med 1998; 338 (1): 35–45PubMedCrossRefGoogle Scholar
  67. 67.
    Volgman AS, Carberry PA, Stambler B, et al. Conversion efficacy and safety of intravenous ibutilide compared with intravenous procainamide in patients with atrial flutter or fibrillation. J Am Coll Cardiol 1998; 31 (6): 1414–9PubMedCrossRefGoogle Scholar
  68. 68.
    Lundstrom T, Ryden L. Chronic atrial fibrillation. Long-term results of direct current conversion. Acta Med Scand 1988; 223 (1): 53–9PubMedCrossRefGoogle Scholar
  69. 69.
    Reimold SC, Maisel WH, Antman EM. Propafenone for the treatment of supraventricular tachycardia and atrial fibrillation: a meta-analysis. Am J Cardiol 1998; 82: 66N-71NCrossRefGoogle Scholar
  70. 70.
    Naccarelli GV, Dorian P, Hohnloser SH, et al. Prospective comparison of flecainide versus quinidine for the treatment of paroxysmal atrial fibrillation/flutter. The Flecainide Multicenter Atrial Fibrillation Study Group. Am J Cardiol 1996; 77 (3): 53A-59ACrossRefGoogle Scholar
  71. 71.
    Falk RH, Pollak A, Singh SN, et al. Intravenous dofetilide, a class III antiarrhythmic agent, for the termination of sustained atrial fibrillation or flutter. Intravenous Dofetilide Investigators. J Am Coll Cardiol 1997; 29 (2): 385–90PubMedCrossRefGoogle Scholar
  72. 72.
    Norgaard BL, Wachtell K, Christensen PD, et al. Efficacy and safety of intravenously administered dofetilide in acute termination of atrial fibrillation and flutter: a multicenter, randomized, double-blind, placebo-controlled trial. Danish Dofetilide in Atrial Fibrillation and Flutter Study Group. Am Heart J 1999; 137 (6): 1062–9PubMedCrossRefGoogle Scholar
  73. 73.
    McClellan KJ, Markham A. Dofetilide: a review of its use in atrial fibrillation and atrial flutter. Drugs 1999; 58 (6): 1043–59PubMedCrossRefGoogle Scholar
  74. 74.
    Zarembski DG, Nolan Jr PE, Slack MK, et al. Treatment of resistant atrial fibrillation. A meta-analysis comparing amiodarone and flecainide. Arch Intern Med 1995; 155 (17): 1885–91PubMedCrossRefGoogle Scholar
  75. 75.
    Podrid PJ. Amiodarone: reevaluation of an old drug. Ann Intern Med 1995; 122: 689–700PubMedGoogle Scholar
  76. 76.
    Opolski G, Stanislawska J, Gorecki A, et al. Amiodarone in restoration and maintenance of sinus rhythm in patients with chronic atrial fibrillation after unsuccessful direct-current cardioversion. Clin Cardiol 1997; 20 (4): 337–40PubMedCrossRefGoogle Scholar
  77. 77.
    Stafford RS, Singer DE. Recent national patterns of warfarin use in atrial fibrillation. Circulation 1998; 97 (13): 1231–3PubMedCrossRefGoogle Scholar
  78. 78.
    Reiffel JA. Selecting an antiarrhythmic agent for atrial fibrillation should be a patient-specific, data-driven decision. Am J Cardiol 1998; 82: 72N-81NCrossRefGoogle Scholar
  79. 79.
    Dell’ Orfano JT, Luck JC, Wolbrette DL, et al. Drugs for conversion of atrial fibrillation. Am Fam Physician 1998; 58 (2): 471–80Google Scholar
  80. 80.
    Jung F, DiMarco JP. Treatment strategies for atrial fibrillation. Am J Med 1998; 104 (3): 272–86PubMedCrossRefGoogle Scholar
  81. 81.
    Kowey PR, Marinchak RA, Rials SJ, et al. Acute treatment of atrial fibrillation. Am J Cardiol 1998; 81: 16C-22CCrossRefGoogle Scholar
  82. 82.
    Naccarelli GV, Dell’ Orfano JT, Wolbrette DL, et al. Cost-effective management of acute atrial fibrillation: role of rate control, spontaneous conversion, medical and direct current cardioversion, transesophageal echocardiography, and antiembolic therapy. Am J Cardiol 2000; 85: 36D-45DCrossRefGoogle Scholar
  83. 83.
    Murdock DK, Schumock GT, Kaliebe J, et al. Clinical and cost comparison of ibutilide and direct-current cardioversion for atrial fibrillation and flutter. Am J Cardiol 2000; 85 (4): 503–6PubMedCrossRefGoogle Scholar
  84. 84.
    Li H, Natale A, Tomassoni G, et al. Usefulness of ibutilide in facilitating successful external cardioversion of refractory atrial fibrillation. Am J Cardiol 1999; 84 (9): 1096–8PubMedCrossRefGoogle Scholar
  85. 85.
    Murray KT. Ibutilide. Circulation 1998; 97 (5): 493–7PubMedCrossRefGoogle Scholar
  86. 86.
    Disch DL, Greenberg ML, Holzberger PT, et al. Managing chronic atrial fibrillation: a Markov decision analysis comparing warfarin, quinidine, and low-dose amiodarone. Ann Intern Med 1994; 120 (6): 449–57PubMedGoogle Scholar
  87. 87.
    Middlekauff HR, Stevenson WG, Gornbein JA. Antiarrhythmic prophylaxis vs warfarin anticoagulation to prevent thromboembolic events among patients with atrial fibrillation. A decision analysis. Arch Intern Med 1995; 155 (9): 913–20PubMedCrossRefGoogle Scholar
  88. 88.
    Greenberg ML, Malenka DJ, Disch DL. Therapeutic strategies for atrial fibrillation. The value of decision analysis. Cardiol Clin 1996; 14 (4): 623–40PubMedCrossRefGoogle Scholar
  89. 89.
    Vorperian VR, Havighurst TC, Miller S, et al. Adverse effects of low dose amiodarone: a meta-analysis. J Am Coll Cardiol 1997; 30: 791–8PubMedCrossRefGoogle Scholar
  90. 90.
    Jessurun GAJ, Crijns HJGM. Amiodarone pulmonary toxicity. BMJ 1997; 314: 619–20PubMedCrossRefGoogle Scholar
  91. 91.
    Pauker S, Eckman M. Finding what you seek: analyzing therapies for nonvalvular atrial fibrillation. Ann Intern Med 1999; 130: 690–1PubMedGoogle Scholar
  92. 92.
    Prystowsky EN. Proarrhythmia during drug treatment of supraventricular tachycardia: paradoxical risk of sinus rhythm for sudden death. Am J Cardiol 1996; 78: 35A-41APubMedCrossRefGoogle Scholar
  93. 93.
    Maisel WH, Kuntz KM, Reimold SC, et al. Risk of initiating antiarrhythmic drug therapy for atrial fibrillation in patients admitted to a university hospital. Ann Intern Med 1997; 127: 281–4PubMedGoogle Scholar
  94. 94.
    Planning and Steering Committee of the AFFIRM Study. Atrial Fibrillation Follow-Up Investigation of Rhythm Management - the AFFIRM Study design. Am J Cardiol 1997; 79: 1198–202CrossRefGoogle Scholar
  95. 95.
    Echt D, Liebson P, Mitchell L. Mortality and morbidity in patients receiving encainide, flecainide, or placebo: the Cardiac Arrhythmia Suppression Trial. N Engl J Med 1991; 324: 781–8PubMedCrossRefGoogle Scholar
  96. 96.
    Flaker GC, Blackshear JL, McBride R, et al. Antiarrhythmic drug therapy and cardiac mortality in atrial fibrillation. J Am Coll Cardiol 1992; 20: 527–32PubMedCrossRefGoogle Scholar
  97. 97.
    Falk RH. Proarrhythmia in patients treated for atrial fibrillation or flutter. Ann Intern Med 1992; 117: 141–50PubMedGoogle Scholar
  98. 98.
    Friedman PL, Stevenson WG. Proarrhythmia. Am J Cardiol 1998; 82: 50N-8NCrossRefGoogle Scholar
  99. 99.
    Chung MK, Schweikert RA, Wilkoff BL, et al. Is hospital admission for initiation of antiarrhythmic therapy with sotalol for atrial arrhythmias required? Yield of in-hospital monitoring and prediction of risk for significant arrhythmia complications. J Am Coll Cardiol 1998; 32 (1): 169–76PubMedCrossRefGoogle Scholar
  100. 100.
    Pinski SL, Helguera ME. Antiarrhythmic drug initiation in patients with atrial fibrillation. Prog Cardiovasc Dis 1999; 42: 75–90PubMedCrossRefGoogle Scholar
  101. 101.
    Simons G, Eisenstein E, Shaw L, et al. Cost-effectiveness of inpatient initiation of antiarrhythmic therapy for supraventricular tachycardias. Am J Cardiol 1997; 80: 1551–7PubMedCrossRefGoogle Scholar
  102. 102.
    Marcus FI. Risks of initiating therapy with sotalol for treatment of atrial fibrillation. J Am Coll Cardiol 1998; 32: 177–80PubMedCrossRefGoogle Scholar
  103. 103.
    Prystowsky EN. Perspectives and controversies in atrial fibrillation. Am J Cardiol 1998; 82 (4A): 3I-6ICrossRefGoogle Scholar
  104. 104.
    Mayet J, More RS, Sutton GC. Anticoagulation for cardioversion of atrial arrhythmias. Eur Heart J 1998; 19 (4): 548–52PubMedCrossRefGoogle Scholar
  105. 105.
    Black I, Fatkin D, Sagar K, et al. Exclusion of atrial thrombus by transesophageal echocardiography does not preclude embolism after cardioversion of atrial fibrillation. Circulation 1994; 89: 2509–13PubMedCrossRefGoogle Scholar
  106. 106.
    Seto TB, Taira DA, Tsevat J, et al. Cost-effectiveness of transesophageal echocardiographic-guided cardioversion: a decision analytic model for patients admitted to the hospital with atrial fibrillation. J Am Coll Cardiol 1997; 29: 122–30PubMedCrossRefGoogle Scholar
  107. 107.
    Seto TB, Taira DA, Manning WJ. Cardioversion in patients with atrial fibrillation and left atrial thrombi on initial transesophageal echocardiography: should transesophageal echocardiography be repeated before elective cardioversion? A cost-effectiveness analysis. J Am Soc Echocardiogr 1999; 12 (6): 508–16PubMedCrossRefGoogle Scholar
  108. 108.
    Klein A. Assessment of cardioversion using transesophageal echocardiography multicenter study. Clin Cardiol 2000; 23: 458Google Scholar
  109. 109.
    Roy D, Talajic M, Dorian P, et al. Amiodarone to prevent recurrences of atrial fibrillation. N Engl J Med 2000; 342: 913–20PubMedCrossRefGoogle Scholar
  110. 110.
    Page R, Wilkinson W, Clair W, et al. Asymptomatic arrhythmias in patients with symptomatic paroxysmal atrial fibrillation and paroxysmal supraventricular tachycardia. Circulation 1994; 89: 224–7PubMedCrossRefGoogle Scholar
  111. 111.
    Thibault B, Nattel S. Optimal management with class I and class III antiarrhythmic drugs should be done in the outpatient setting: protagonist. J Cardiovasc Electrophysiol 1999; 10: 472–81PubMedCrossRefGoogle Scholar
  112. 112.
    Myerburg R, Kloosterman M, Yamamura K, et al. The case for inpatient initiation of antiarrhythmic therapy. J Cardiovasc Electrophysiol 1999; 10: 482–7PubMedCrossRefGoogle Scholar
  113. 113.
    Guerra P, Lesh M. The role of nonpharmacologic therapies for the treatment of atrial fibrillation. J Cardiovasc Electrophysiol 1999; 10: 450–60PubMedCrossRefGoogle Scholar
  114. 114.
    Cannom DS. Atrial fibrillation: nonpharmacologic approaches. Am J Cardiol 2000; 85: 25D-35DCrossRefGoogle Scholar
  115. 115.
    Narasimhan C, Blanck Z, AkhtarM. Atrioventricular nodalmodification and atrioventricular junctional ablation for control of ventricular rate in atrial fibrillation. J Cardiovasc Electrophysiol 1997; 9: S146–150Google Scholar
  116. 116.
    Brignole M, Menozzi C, Gianfrachi L, et al. Assessment of atrioventricular junction ablation and VVIR pacemaker versus pharmacological treatment in patients with heart failure and chronic atrial fibrillation. Circulation 1998; 98: 953–60PubMedCrossRefGoogle Scholar
  117. 117.
    Haissaguerre M, Shah D, Jais P, et al. Role of catheter ablation for atrial fibrillation. Curr Opin Cardiol 1997; 12: 18–23PubMedCrossRefGoogle Scholar
  118. 118.
    Lau C, Tse H, Lok N, et al. Initial experience with an implantable human atrial defibrillator. PACE 1997; 20: 220–5PubMedCrossRefGoogle Scholar
  119. 119.
    Brignole M, Gianfranchi L, Menozzi C, et al. Influence of atrioventricular junction radiofrequency ablation in patients with chronic atrial fibrillation and flutter on quality of life and cardiac performance. Am J Cardiol 1994; 74: 242–6PubMedCrossRefGoogle Scholar
  120. 120.
    Ellenbogen KA, Chung MK, Asher CR, et al. Postoperative atrial fibrillation. Adv Card Surg 1997; 9: 109–30PubMedGoogle Scholar
  121. 121.
    VanderLugt JT, Mattioni T, Denker S, et al. Efficacy and safety of ibutilide fumarate for the conversion of atrial arrhythmias after cardiac surgery. Circulation 1999; 100 (4): 369–75PubMedCrossRefGoogle Scholar
  122. 122.
    Ezekowitz M. Atrial fibrillation: the epidemic of the new millennium. Ann Intern Med 1999; 131: 537–8PubMedGoogle Scholar
  123. 123.
    Kowey PR, Marinchak RA, Rials SJ, et al. Atrial fibrillation trials: will they teach us what we need to know? Am J Cardiol 1998; 82: 86N-91NCrossRefGoogle Scholar

Copyright information

© Adis International Limited 2000

Authors and Affiliations

  • Mark P. Teng
    • 1
  • Edward Catherwood
    • 1
  • Daniel P. Melby
    • 2
  1. 1.Cardiology DivisionDartmouth-Hitchcock Medical CenterLebanonUSA
  2. 2.Division of Internal MedicineDartmouth-Hitchcock Medical CenterLebanonUSA

Personalised recommendations